MCL LEADS IN MEDICAL CANNABIS WITH CANADIAN DEAL
Post# of 106716
(Total Views: 275)
Posted On: 03/23/2018 12:01:29 PM
MCL LEADS IN MEDICAL CANNABIS WITH CANADIAN DEAL
January 8, 2018 8th January 2018
• VitaCann Pty Ltd (“VitaCann”) has signed an exclusive joint venture agreement (the “Joint Venture”) for a World First Pharmaceutical Grade Medical Cannabis Extended Release Pill with Canntab Therapeutics Limited (“Canntab”) of Toronto, Ontario, Canada.
QBL emerging as key player in medicinal cannabis scene
January 9, 2018
(See board, website and Facebook webpage for more information)
https://www.queenslandbauxite.com/single-post...Production
MCL Escalates Hemp Seed Food Production
December 27, 2017
MCL and AEB join to develop Cannabis veterinary medications
December 22, 2017
Breakthrough for GMP Quality Medicinal Cannabis
December 11, 2017
Australia’s largest hemp food production underway
December 7, 2017
VITAHEMP IN DEMAND TO THE LAST ITEM!
December 4, 2017
VitaHemp Product Launch – Australian Grown Goodness
November 27, 2017
Momentous Deal with Premium Hemp Processing and Innovation Group
November 22, 2017
• VitaCann is a wholly owned subsidiary of Medical Cannabis Limited (“MCL”), subsidiary of Queensland Bauxite Limited (ASX:QBL),
• MCL believes this product to be a game changing medicinal solution
• New Australian Federal Government export approval gives MCL clear and tangible opportunities to expand production, processing and manufacture of its unique Cannabis seed bank, genetics and products into the existing worldwide multi-billion dollar markets.
• The Australian Government has willingly put in place legislation to enable a consistent pharmaceutical grade GMP quality pill product such as the Canntab pill now secured by VitaCann, to be approved as a general prescription medication subject to an established approval process.
This is unlike the legislative framework for current medical cannabis products being produced by nearly all other cannabis companies that without a consistent pharmaceutical grade product may find it difficult to get approvals.
• Doctors will be more comfortable prescribing a pharmaceutical grade pill rather than allowing patients to smoke cannabis.
• This XR pill is aimed to address the concerns raised by politicians, policy makers, medical professionals and medical cannabis patients who are looking for a better cannabis medicine delivery option (see below)
• Possible solution to the opioid crisis
• Canntab currently have several formulations of this pill to treat a variety of illnesses
The Board of QBL is excited to be involved with this World First venture
The Board of QBL is thrilled to be involved in bringing to Australia, through its subsidiary MCL, a
Queensland Bauxite Limited | 24 Birriga Rd | Bellevue Hill NSW 2023
Ph. 02 9291 9000 | Fax 02 9291 9099 | Email :info@queenslandbauxite.com.au | Mailing Address PO Box 114 Bondi NSW 2026
Read More: https://investorshangout.com/post/view?id=491...z59zv6qKhY
Read More: https://investorshangout.com/post/view?id=497...z5AaTIFVMF
January 8, 2018 8th January 2018
• VitaCann Pty Ltd (“VitaCann”) has signed an exclusive joint venture agreement (the “Joint Venture”) for a World First Pharmaceutical Grade Medical Cannabis Extended Release Pill with Canntab Therapeutics Limited (“Canntab”) of Toronto, Ontario, Canada.
QBL emerging as key player in medicinal cannabis scene
January 9, 2018
(See board, website and Facebook webpage for more information)
https://www.queenslandbauxite.com/single-post...Production
MCL Escalates Hemp Seed Food Production
December 27, 2017
MCL and AEB join to develop Cannabis veterinary medications
December 22, 2017
Breakthrough for GMP Quality Medicinal Cannabis
December 11, 2017
Australia’s largest hemp food production underway
December 7, 2017
VITAHEMP IN DEMAND TO THE LAST ITEM!
December 4, 2017
VitaHemp Product Launch – Australian Grown Goodness
November 27, 2017
Momentous Deal with Premium Hemp Processing and Innovation Group
November 22, 2017
• VitaCann is a wholly owned subsidiary of Medical Cannabis Limited (“MCL”), subsidiary of Queensland Bauxite Limited (ASX:QBL),
• MCL believes this product to be a game changing medicinal solution
• New Australian Federal Government export approval gives MCL clear and tangible opportunities to expand production, processing and manufacture of its unique Cannabis seed bank, genetics and products into the existing worldwide multi-billion dollar markets.
• The Australian Government has willingly put in place legislation to enable a consistent pharmaceutical grade GMP quality pill product such as the Canntab pill now secured by VitaCann, to be approved as a general prescription medication subject to an established approval process.
This is unlike the legislative framework for current medical cannabis products being produced by nearly all other cannabis companies that without a consistent pharmaceutical grade product may find it difficult to get approvals.
• Doctors will be more comfortable prescribing a pharmaceutical grade pill rather than allowing patients to smoke cannabis.
• This XR pill is aimed to address the concerns raised by politicians, policy makers, medical professionals and medical cannabis patients who are looking for a better cannabis medicine delivery option (see below)
• Possible solution to the opioid crisis
• Canntab currently have several formulations of this pill to treat a variety of illnesses
The Board of QBL is excited to be involved with this World First venture
The Board of QBL is thrilled to be involved in bringing to Australia, through its subsidiary MCL, a
Queensland Bauxite Limited | 24 Birriga Rd | Bellevue Hill NSW 2023
Ph. 02 9291 9000 | Fax 02 9291 9099 | Email :info@queenslandbauxite.com.au | Mailing Address PO Box 114 Bondi NSW 2026
Read More: https://investorshangout.com/post/view?id=491...z59zv6qKhY
Read More: https://investorshangout.com/post/view?id=497...z5AaTIFVMF
(0)
(0)
Robert